Boletín Médico del Hospital Infantil de México (Sep 2015)

Retinoblastoma in Mexico: part I. A review of general knowledge of the disease, diagnosis, and management

  • Van C. Lansingh,
  • Kristen A. Eckert,
  • Barrett G. Haik,
  • Blanca X. Phillipps,
  • Vanessa Bosch-Canto,
  • Carlos Leal-Leal,
  • Marco A. Ramírez-Ortiz

DOI
https://doi.org/10.1016/j.bmhimx.2015.09.001
Journal volume & issue
Vol. 72, no. 5
pp. 299 – 306

Abstract

Read online

This is the first of a two-part review that aims to report the current knowledge of retinoblastoma (Rb) and its implications in Mexico (including the authors’ experience at the leading Rb centers), identify the gaps in practice, and propose solutions to improve diagnosis, treatment, and patient uptake. In this first part, general knowledge of Rb diagnosis and management is summarized with a focus on the latest advances in chemotherapy. A general review of peer-reviewed literature of Rb was conducted on PubMed. Key findings were summarized. Provided there is early detection and referral of patients followed by appropriate conservative management, Rb is curable. In developed countries, the primary treatment outcome is ocular salvage with sight preservation. Advanced chemotherapeutic options such as intra-arterial and intravitreal chemotherapy can now save even the most advanced tumors. Advances in Rb therapy are generally limited to developed countries. The implications in Mexico, of the findings from this review will be discussed in Part 2, which will be a comprehensive situational analysis of the state of Rb programming in Mexico, including a review of current demographic data available from hospitals that have Rb programs or treat Rb.

Keywords